← Back to Search

Cytokine

Vaccine + IL-2 for Sarcoma and Neuroblastoma

Phase 1

Waitlist Available

Research Sponsored by Milton S. Hershey Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of Ewing's sarcoma OR neuroblastoma

Performance status Lansky 70-100% OR ECOG 0-2

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying vaccine therapy when given with IL-2 to see how well it works in treating young patients with relapsed or refractory Ewing's sarcoma or neuroblastoma.

Who is the study for?

This trial is for young patients aged 1 to 30 with relapsed or refractory Ewing's sarcoma or neuroblastoma. They should have a life expectancy of at least 8 weeks, be in relatively good health (Lansky score of 70-100% or ECOG score of 0-2), and have normal liver and kidney function tests. Participants must not be pregnant, agree to use contraception if fertile, and test negative for certain viruses including HIV and hepatitis.Check my eligibility

What is being tested?

The trial is testing the effectiveness of a personalized vaccine therapy combined with Interleukin-2 (IL-2) in stimulating the immune system to fight cancer cells. The vaccine is made from the patient's own tumor cells and white blood cells, aiming to trigger a strong immune response against the cancer.See study design

What are the potential side effects?

Potential side effects may include reactions related to strengthening the immune system such as fever, chills, fatigue, rash, nausea; IL-2 can also cause low blood pressure, fluid retention and impact organ function due to an increased immune response.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Ewing's sarcoma or neuroblastoma.

Select...

I can carry out daily activities with little to no assistance.

Select...

My condition has returned or didn't respond to treatment.

Select...

My kidneys are functioning well.

Select...

I have tested positive for the Epstein-Barr virus.

Select...

I am between 1 and 30 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Milton S. Hershey Medical CenterLead Sponsor

492 Previous Clinical Trials

2,798,812 Total Patients Enrolled

3 Trials studying Sarcoma

62 Patients Enrolled for Sarcoma

Kenneth G. Lucas, MDStudy ChairMilton S. Hershey Medical Center

9 Previous Clinical Trials

97 Total Patients Enrolled

3 Trials studying Sarcoma

35 Patients Enrolled for Sarcoma

Media Library

Interleukin-2 (Cytokine) Clinical Trial Eligibility Overview. Trial Name: NCT00101309 — Phase 1

Sarcoma Clinical Trial 2023: Interleukin-2 Highlights & Side Effects. Trial Name: NCT00101309 — Phase 1

Interleukin-2 (Cytokine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00101309 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings in this research program?

"Contrary to what is registered on clinicaltrials.gov, this medical investigation has ceased taking in patients; the trial was posted 11th of November 2004 and last edited 17th December 2013. However, there are 574 alternative studies that presently require human participation."

Answered by AI

Do I meet the qualifications to participate in this trial?

"This clinical trial requires 10 participants aged between 1 and 30 years with a diagnosed case of neuroblastoma. Furthermore, the following criteria must be met: performance status Lansky 70-100% OR ECOG 0-2; life expectancy 8 weeks or more; hepatic function normal to relapsed/refractory disease."

Answered by AI

Does this research endeavor include individuals aged 25 and over?

"The rules regulating who can be enrolled in this trial stipulate that prospective participants must between 1 and 30 years of age."

Answered by AI

What potential risks are associated with this particular therapy?

"This novel treatment has yet to be extensively tested, so it was given a score of 1. This implies that there is limited data supporting the drug's efficacy and safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma

2004. "Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00101309.

All > Sarcoma > Neuroblastoma